Angiogenesis is critical in the progression of breast cancer, and knockout of SRC-1 reduces the microvessel density (MVD) of breast cancer cells and inhibits angiogenesis in xenograft tumours, and these effects can be rescued by VEGFa treatment [72]. Here, SRC is linked to breast cancer.